Qilu Pharmaceutical Files for Hong Kong IPO with $1.02 Billion in 2024 Export Revenue
Qilu Pharmaceutical
Specialty Formulations and Active Pharmaceutical Ingredients (API) Developer
▲March 6-7New Drug Innovators SummitScan to Register
Note:This article does not constitute any investment opinions or suggestions., please refer to the official/company announcement; this article only introduces drugs related to medical health, not a recommendation of treatment plans (if involved), and does not represent the platform's position. Any article reproduced requires authorization.
PharmaCircleLearned:In the future, Qilu Pharmaceutical will continue to focus on patients' needs, developing more high-quality medicines to benefit patients worldwide. In the past five years, R&D investment exceeded 13.5 billion yuan, with a team of over 5,000 researchers. In 2024, export value reached 1.02 billion US dollars, approximately 7.436 billion yuan.
Copyright Statement: This article is reproduced from PharmaCircle Info，Media or individuals who do not wish to be reproduced can contact us, and we will delete it immediately.
Agenda is being updated and will be subject to the actual conference.
09:00-09:25
Trends and Opportunities in the Development of Innovative Drugs in 2025
Wang XingliFosun Pharma, Executive President & Co-CEO of the Innovative Drug Division
09:25-09:50
Commercialization Pathways for Innovative Drugs/Improved New Drugs under the Background of Centralized Procurement and National Negotiations (Tentative)
Liu QianGeneral Manager of AstraZeneca China, Respiratory and Digestive Diseases Business Unit
09:50-10:15
How CR Pharma Faces the Uncertainty of 2025
Cui XingpinChina Resources Pharmaceutical, Vice President
10:15-10:40
Tea Break
10:40-11:05
Accelerate Innovation, Embrace the World, and Open a New Chapter of Growth
Xie XinChina Biopharmaceutical, Executive Director, Senior Vice President
11:05-11:30
Through AI and Big Data: Future Insights and Innovation Prospects in Biomedical R&D
Gong YuanxiangPresident of Zhuhai Hengqin Haomai Technology Co., Ltd.
11:30-12:00
Roundtable: Cooperation + Going Global, Pushing Chinese Innovation onto the World Stage
1. What are the impacts of the NewCo model's popularity on pharmaceutical R&D? What effects has it brought to China's innovative drug capital market?
2. Key Points for Choosing the Path of Product Pipeline Overseas Expansion
3. Project transfer overseas, newco, formulation export, and API export: What are the pain points and obstacles for each (e.g., economic cycles, trade protectionism, local competition, trust, etc.)?
Zhao XiaolinLilly China Innovation Collaboration Center, Senior Advisor for External Innovation Collaboration
Wang JunLingke Pharmaceuticals, CSO
Cui HaifengJi Min Trust Group Shanghai Ji Yu Pharmaceutical, VP&CSO
Hong JunTianjing Biopharma, Vice President of Global Business Development
Cao FeiYing Shi Bio, Co-Founder/Chief Operating Officer
Wang XinguangFormer GSK, Head of Communications, Government Affairs and Market Access
12:00-13:30
Lunch
13:30-13:55
USP Quality Standards for Therapeutic Monoclonal Antibodies
Cen GuoshanUS Pharmacopeial Convention, Vice President and General Manager of Greater China
13:55-14:20
Research and Development of Tumor Immunostimulants and Multi-Antibody Prodrug Molecules
Jiang WeidongKangkang Bio, CEO
14:20-14:45
How to Design the Next Generation of ADCs to Improve the Therapeutic Window
Gao ChangshouAilis Pharmaceutical, Chief Technology Officer
14:45-15:10
Nonclinical Safety Evaluation Strategies and Case Studies of ADC Drugs
Zhou LiTianqin Biotech, Executive Vice President; Chairman of the Reproductive Toxicology Professional Committee of the Chinese Society of Toxicology
15:10-15:35
Extracellular Cleavage Linker Iterative Update of ADC
Cai JiaqiangYilian Biotechnology (Suzhou), Co-Founder, CSO
15:35-16:00
Frontier Exploration of Radiopharmaceuticals in Clinical Applications
Single WaveBo Rui Chuang He (Suzhou), CEO
16:00-16:25
Research Challenges and Application Prospects of Multispecific Antibody Drugs
High-TechImmune Ark, Founder, Chairman and CEO
16:25-16:50
Application of BioAI Models in the Early Research of Antibody Drugs
Liu JianghaiShengshi Junlian, Founder & General Manager
16:50-17:15
Sixin Pharmaceutical
17:15-17:40
The Epic Transformation of One-Click Large Model Writing for Any Pharmaceutical Development Report
Li XingBeijing Deep Intelligence Technology Co., Ltd., CEO
09:00-09:25
From the Blossoms of JPM, Seeking Strategies for Survival and Growth of Biotech Startups: The Overseas Expansion Chapter
Cai XuejunFormer BMS, Global Vice President of R&D
09:25-09:50
Breaking the Deadlock and Reflections on the Overseas Expansion of Innovative Drugs
Sheng Yan CiHenlius, General Manager of Global Strategy and Project Management
09:50-10:15
Advances in Small Molecule New Drugs
Hu YonghanXinnov, CTO
10:15-10:30
Tea Break
10:30-10:55
Analysis of Key Factors in Clinical Development and Registration for Innovative Drugs Going Overseas
Xiao ShenHaisen Bio, Chief Medical Officer
10:55-11:20
Global Progress in the Development of New Anti-Influenza Virus Drugs
Chen XiaoxinZhongsheng Ruichuang, Co-Founder, Director, President
11:20-12:00
Roundtable Dialogue: Development Layout and Trends in Small Molecule Innovative Drug Research
Zhang HanchengYingchuang Pharmaceuticals, Chairman & President
Cai XuejunFormer BMS, Global R&D Vice President
Sheng YanciFuhong Hanlin, General Manager of Global Strategy and Project Management
Hu YonghanXinnovis, CTO
Xiao ShenHaisen Bio, Chief Medical Officer
12:00-13:30
Lunch
High-Potential Pharmaceutical Enterprises Showcase
13:30-13:55
From Single-Cell Technology to Disruptive Treatment Strategies
Xu XuanhaoBioRay Laboratories, Single-Cell Medical Scientist
13:55-14:20
Development of Innovative Drugs for Chronic Pain Based on the Multimodal Analgesia Concept
Wang YouxinLidao Pharmaceuticals, Chairman and CEO
14:20-14:45
NPTXR: New First in class target receptor for platform therapy of Solid tumors
Chen BozhouCalithera Biosciences, Co-Founder and CEO
14:45-15:10
EP4 Antagonist: Paving a New Path for Cartilage Regeneration in Osteoarthritis
Deng YongqiKaifeng Pharmaceutical, Founder & CEO
15:10-15:30
Guest Itinerary Confirmation in Progress
15:30-15:55
Tea Break
15:55-16:20
Explore the Etiology of Autoimmune Diseases to Develop New Curative Drugs
Fan GuohuangAmephibio, Chairman
16:20-16:45
From Best-in-Class to First-in-Class (Indication): Development Strategy for a Potent Dual Selective JAK Inhibitor
Shen WangVivow Biotech, CEO
16:45-17:10
Development of IKZF1/3 Molecular Glue Degraders
Liwén ZhàoChaoyang Pharmaceutical, CEO
17:10-17:35
PolysaccharideInnovative Drug Platform GlycoTDS™ and Targeted Anti-Tumor New Drug Industrialization
Wang SiSuzhou Shengdu Likang Pharmaceutical Co., Ltd., Founder/CEO
13:30-14:00
Case Study: SINOVAC Biotech's Collaboration with China's Biopharmaceutical Enterprises for International Expansion
Shao KeSinovac Biotech Ltd., Vice General Manager
14:00-14:30
Shanghai Pharmaceutical Southeast Asia and MENA Market Expansion Experience Sharing
Yan JunGeneral Manager of Shanghai Pharmaceutical International Business Division
14:30-15:00
Pharmaceutical Companies Going Global: The Role and Regulatory Requirements of the FDA
Wang YapingFormer FDA Review Expert; Blue Magpie Bio, CMO of Therapeutic Products
15:00-15:30
Quality Assurance and Regulatory Requirements for Innovative Drug Products Going Overseas
Du XinEglin, Co-founder & CEO
15:30-15:55
Tea Break
15:55-16:25
Current Status and Opportunities in BD of the Biopharmaceutical Industry and Protein Degradation Field in Recent Years
Zhou FengHangzhou Hezheng Pharmaceutical, Chief Strategy Officer
16:25-16:55
EU Pharmaceutical Regulatory Policies and Regulations
16:55-17:30
Roundtable Dialogue: Opportunities and Challenges for Pharmaceutical Companies Going Global (Policy, Market, Clinical)
Cai XuejunFormer BMS, Global R&D Vice President (Moderator)
Shao KeSinovac Biotech, VP
Yan JunGeneral Manager of Shanghai Pharmaceutical International Business Division
Zhou FengHangzhou Hezheng Pharmaceutical, Chief Strategy Officer
09:00-09:25
Design of Lipid Nanocarriers and Their Exploration in RNA Drug Development
Zhang XueqingRongcan Bio, Chief Scientist
09:25-09:50
A Novel Small Nucleic Acid Delivery System: QTsome™
Lin JialiangHaichang Bio, Head of Delivery System Research and Development at the New Drug Research and Development Center
09:50-10:15
Crossing the CGT Original Innovation Death Valley through Open Innovation - A Case Study of Targeted Integration of Large Gene Fragments in Cell Therapy
Xie XuanhuiReindeer Bio, Chief Innovation and Investment Officer
10:15-10:35
Tea Break
10:35-11:00
The Practice of AI in Efficiently Discovering Clinical Candidate Drugs
Xing LiLangrui Bio, CEO
11:00-11:25
Key Points for IND Submission of Nucleic Acid Vaccines
Lu HangJIAYI Bio, CEO
11:25-11:50
Development of In vivo CAR-T Therapy Based on LNP-mRNA Technology
Hu RongkuanXingrui Medicine, Chairman and CEO
11:50-13:30
Lunch
13:30-13:55
Rational Design of Nucleic Acid Drug Sequences Sharing
Pan JuanEdding Pharma, Preclinical R&D Director
13:55-14:20
Obesity/Weight Loss Drug Development (Proposed)
Jing ShuqianHongyun Hua Ning, Founder, Chairman and CEO
14:20-14:45
Case Study on the Identification of Semaglutide and Tirzepatide Impurities
Liu GuozhuChenchen Pharmaceuticals, Founder & Chairman
14:45-15:10
Research on Artificial Intelligence-Based Protein Drug Design Methods and GLP-1 Polypeptide Drug Practice
Chen HaifengShanghai Jiao Tong University, Professor; Co-founder of Zhiyaoyuanchuang
15:10-15:35
Development of New Drugs Based on Survival Strategy Animal Toxin Peptides
Rong MingqiangPed Bio, Chairman
15:35-16:00
Stability Modification and Pharmacokinetic Analysis of FGF21 Analogues
Zhou ZhenxingDoer Biologics, Senior Director of Bioanalysis
16:00-16:25
Medical Concept Validation and Minimally Invasive Interventional Drug Delivery Technology Platform
Li YongyongTongji University, School of Medicine, Professor
09:00-09:30
Protein Degradation Dual Platform (GlueTacs®) Driven Tumor and Immunotherapy Drug Development
Yang XiaobaoFounder, Chairman, and CEO of Biaoxin Bio
09:30-10:00
Advances in Transdermal Delivery Technology and New Drug Development
Sheng XiaoxiaLeading Pharmaceuticals, CEO
10:00-10:30
Late-stage CMC and NDA Submission Practices for Small Molecule Innovative Drugs (Tentative)
Liu Juntao
BeiGene, Director of Process Development
10:30-10:50
A good process is crucial for small-molecule new drug development.
Fu Peng
Muhon Chemical, CEO
10:50-11:20
Mitochondrial Uncouplers and Their Applications in the Field of Metabolic Diseases
Ma TianweiPresident of Junsheng Tai Medical Translational Science Academy
11:20-11:50
Pharmaceutical Considerations in the Clinical Translation of Small-Molecule Innovative Drugs
Li YongguoJiayue Pharmaceuticals, Chairman & CSO
11:50-12:10
ACT001 Combined with Radiotherapy: A Breakthrough Treatment for Brain Metastases in Small Cell Lung Cancer in China
Chen Yue Shangde Pharmaceutical, Founder & Chairman
12:10-13:30
Lunch
13:30-14:00
Current Status and Future Directions in Pain Management Drug Development
Chen Bozhou
Calithera Biosciences, Co-Founder and CEO
14:00-14:30
Discovery of Novel A2aR/A2bR Antagonists for Cancer Immunotherapy (Proposed)
Wang Yonghui
Fudan University, Distinguished Professor; Lead Discovery Pharmaceuticals, Co-Founder and Chief Scientific Officer
14:30-15:00
In-situ Neural Regeneration Technology of the Brain and Clinical Translation
Chen GongDirector of the Brain Repair Center, Jinan University; Founder and Chairman of NeuroX Biotech
15:00-15:30
Development and Challenges of Proteolysis Targeting Chimeras (PROTAC) Drugs
Zeng LiHepharma, CEO
15:30-16:00
Research on FLT3-ITD Inhibitor Resistance Mechanisms and Development of Innovative Targeted Intervention Strategies
Yang GuangNankai University, College of Pharmacy, Professor & Doctoral Supervisor
16:00-16:30
Progress in Anti-Aging Research and Opportunities for Clinical Innovation Drug Development
Zhang JianJiangsu Lead Biotech, General Manager
16:30-17:00
Synthetic Lethal Drugs: Opportunities, Challenges, and Development Trends
Chen XuxingYouli Bio, Founder, CEO
